PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 16:15:00·⟳ 抓取 16:15:21 +21s·⚡ 决策 08-27 16:30:10 +14m49s·61.1 天前
DJS再次发布Replimune证券集体诉讼征集公告，未披露新增诉讼或监管事实
本条PR Newswire信号与2026-08-07/08-10已公开的Replimune证券集体诉讼征集内容高度一致，核心事实来自2026-04-10 FDA CRL旧事件；没有新增金额、判决、监管进展或公司回应，不能形成新的可交易edge。
📄 原文PR Newswire All News Releases↗ 原文
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL LOS…
不做 Replimune Group, Inc.（REPL.US）
不做：本条是既有证券集体诉讼的律师征集重复公告，核心FDA CRL和诉讼指控均已公开传播，没有新增可交易事实。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件事实是律师事务所再次发布集体诉讼参与提醒，而非新的FDA决定或新的诉讼实质进展；诉讼核心指控和lead plaintiff截止日此前已被多家律所公开传播，且RP1 BLA被拒本身已在4月披露并由股价消化，因此对Replimune Group, Inc.（REPL.US）不构成新的方向性交易信号。
消息传播链
- 公司披露FDA就RP1联合nivolumab治疗晚期黑色素瘤BLA发出Complete Response Letter，这是诉讼指控的基础事实。
- 律所公告称针对Replimune的证券集体诉讼已在马萨诸塞地区法院提交，指控内容与本次DJS公告一致。
- DJS Law Group此前已发布几乎同主题的Replimune诉讼征集公告，说明2026-08-27信号不是首发。
- 本次信号为律师广告式提醒，没有新增诉讼金额、法院裁定、SEC行动或公司公告。
主要风险
- 若后续出现法院受理重大进展、和解金额、SEC介入或公司正式披露新的监管路径变化，需要重新评估。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-07 · 影响 invalidates
反向检查显示诉讼事实和指控此前已公开，不是新的强空催化。
检索:Replimune class action lawsuit August 2026 same allegations DJS Gainey McKenna FDA CRL 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-04-10 · 影响 weakens
基础FDA拒绝事件已在4月由公司官方披露，本条律师公告不改变监管状态。
检索:Replimune FDA CRL RP1 BLA April 10 2026 official 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足不影响结论；不做的核心依据是本条没有新增事实且已有同类公告传播。
方向:重复律师征集公告通常不能作为独立方向性催化；本次不使用先例定方向。
涨幅量级:无新增事实，未用历史反应校准幅度。
形态:证券诉讼征集公告多为旧负面事实的二次传播，交易上容易无新增反应。
原文全文
展开原文 · 1,988 字
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 20, 2025 to April 10, 2026
DEADLINE: October 5, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address the FDA's concerns with its study design contained in its Biologics License Application ("BLA"). Based on these facts, Replimune's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 20, 2025 to April 10, 2026
DEADLINE: October 5, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address the FDA's concerns with its study design contained in its Biologics License Application ("BLA"). Based on these facts, Replimune's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。